Registry-listed formulations

fontolizumab · mesh:C505731

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Completion Rate
    0%(0/1)
    Active Trials
    0(0%)
    Terminated
    1(100%)

    Phase Distribution

    Phase 2
    1
    100%

    Phase Distribution

    0

    Early Stage

    1

    Mid Stage

    0

    Late Stage

    Phase Distribution1 total trials
    Phase 2Efficacy & side effects
    1(100.0%)

    Highest Phase Reached

    Phase 2

    Trial Status & Enrollment

    Completion Rate

    0.0%

    0 of 1 finished

    Non-Completion Rate

    100.0%

    1 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    1

    all time

    Status Distribution
    Terminated(1)

    Detailed Status

    Terminated1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    1
    Active
    0
    Success Rate
    0.0%
    Most Advanced
    Phase 2

    Trials by Phase

    Phase 21 (100.0%)

    Trials by Status

    terminated1100%

    Recent Activity

    0 active trials
    Showing 1 of 1
    terminatedphase_2

    A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis

    NCT00281294

    Clinical Trials (1)

    Showing 1 of 1 trials
    NCT00281294Phase 2

    A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis

    Terminated

    All 1 trials loaded

    Drug Details

    Intervention Type
    Drug
    Molecule Type
    Antibody
    Total Trials
    1

    External References

    ChEMBL
    CHEMBL2108459

    Names & Codes

    Research Codes

    HUZAF